License Agreements - Harvard License Agreement - Additional Information (Details) |
1 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 10, 2021
shares
|
Oct. 31, 2023 |
Jun. 30, 2025
USD ($)
|
May 31, 2021
USD ($)
|
|
| Lilly Agreement | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Agreement description | In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events, of which $25.0 million has been received through June 30, 2025. | |||
| Harvard | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Success payment amount due | $ 0 | $ 15,000,000 | ||
| Harvard | Common Stock | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Issuance of common stock for success payment liability, Shares | shares | 174,825 | |||
| Harvard | Minimum | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Success payments | $ 5,000,000 | |||
| Harvard | Minimum | Series A Preferred Stock | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Success Payments, valuation multiples | 5 | |||
| Harvard | Maximum | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Additional success payment amount due | $ 90,000,000 | |||
| Success payments | $ 105,000,000 | |||
| Harvard | Maximum | Series A Preferred Stock | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Success Payments, valuation multiples | 40 | |||
| Success Payments | Harvard | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Agreement description | The Company is required to make success payments to Harvard during a period of time, or the Harvard Success Payment Period, which has been determined to be the later of (1) the ninth anniversary of the Harvard License Agreement or (2) the earlier of (a) the twelfth anniversary of the Harvard License Agreement and (b) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Harvard Success Payment Period, the Company will perform a calculation of any amounts owed to Harvard on each rolling 90-day period, commencing one year after the Company’s IPO. |